This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to LabCorp (LH) Stock For Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.
Allscripts (MDRX) Unveils Newly Rebranded App Expo Site
by Zacks Equity Research
Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.
Here's Why You Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.
Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe
by Zacks Equity Research
Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.
Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing
by Zacks Equity Research
Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.
Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong
by Zacks Equity Research
Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
by Zacks Equity Research
With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.
ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay
by Zacks Equity Research
ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.
Medtronic (MDT) to Gain From New Reimbursement Program for CGM
by Zacks Equity Research
Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.
Bruker (BRKR) to Improve Spatial Biology With New Launch
by Zacks Equity Research
Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.
Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform
by Zacks Equity Research
The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Here's Why You Should Hold on to STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.